Which blockbuster products could drive the CSL share price higher?

What's going on behind the scenes in the labs of CSL?

| More on:
Two lab technicians wearing white coats discuss results they see on a computer screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the last 10 years, the CSL Limited (ASX: CSL) share price has absolutely smashed the market.

During this time, the biotherapeutics giant's shares have posted an average total return of 18.58% per annum.

To put this into context, this would have turned a $10,000 investment into approximately $55,000.

Why has the CSL share price smashed the market?

Investors have been bidding the CSL share price higher over the last 10 years thanks to its consistently strong earnings growth.

There have been a few key drivers of this impressive growth. Strong demand for CSL's existing therapies, earnings accretive acquisitions, and its lucrative research and development (R&D) pipeline.

The latter is underpinned by a material investment in R&D activities each year by management. And when I say material, I mean it.

Each year, the company reinvests in the region of 11% of its sales back into R&D. This meant an investment of over US$1 billion in FY 2022.

The good news is that this investment means there are plenty of potentially lucrative products on the way that could be the next drivers of growth. But what are they?

What will drive CSL's future growth?

Late last year, Citi commented on CSL's R&D event and highlighted CSL112 as one of the most important products under development. It commented:

The R&D budget is significant at US$1.16bn in FY22 or ~11% of revenue. CSL will continue to spend ~10-11% of revenue on R&D annually. The pipeline now includes assets from recently acquired Vifor with two assets in Phase 3. Our $340 [now $350] TP includes $22.40 for the R&D portfolio (down from $23 on delays) – the main asset remains CSL112 (cardiovascular) at $20/share on which we will get Phase 3 data in Q1 CY24. Maintain Buy, $340 TP.

What is CSL112? It is a novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI). Completion of the trial is expected by the end of the year, which means that, if all goes to plan, it may not be too long until this therapy is generating revenue for CSL.

And what a lot of revenue it could generate! Some analysts estimate that CSL112 could pull in peak sales of US$3 billion. That compares to CSL's total FY 2022 sales of approximately US$10.13 billion.

What else?

And then there's CSL312, also known as garadacimab. This upcoming product has been described as a pipeline within a product by analysts at Goldman Sachs. It explains:

CSL312 is a humanised anti-factor XIIa monoclonal antibody in development for multiple indications including as a subcutaneous therapy for HAE [hereditary angioedema], with the potential for administration every 4 weeks (vs. every 2-3 days for Haegarda). Given its early position in the coagulation cascade, there is also potential application in various other disorders (including fibrosis, cardiovascular and inflammatory indications).

Catherine Milch, CSL's Vice President R&D Immunology, thinks very highly of the product. Milch said:

Based on the data published in The Lancet, we believe garadacimab has the potential to become a transformative first-in-class therapy, providing a new option where there is significant unmet need. The development of garadacimab reflects our commitment to providing life changing medicines for patients with HAE and for the physicians who treat them.

Overall, the future looks bright for CSL and its share price. Especially when you consider that the above are just two of a large (and growing) number of products in its pipeline.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »